Administrative Core

行政核心

基本信息

  • 批准号:
    10514318
  • 负责人:
  • 金额:
    $ 678.15万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-05-16 至 2025-04-30
  • 项目状态:
    未结题

项目摘要

SUMMARY The Administrative Core will coordinate the CAMPP AViDD Center by 1) establishing an organizational structure centered on an Executive Committee responsible for – along with Director, Deputy Directors, and Scientific Advisory Board (SAB) – monitoring overall program progress and making decisions on staffing plans, allocation of resources, core usage, and other policies; 2) coordinating regularly held conference calls between the Center’s research teams and organizing annual meetings between the PIs, selected key personnel, the SAB and NIAID, as well as annual reverse site visits at NIAID; 3) assisting the investigators of this consortium in reagent and data sharing, manuscript preparations, IND preparations, the timely public dissemination of data, and the submission of annual progress reports to NIAID; and 4) providing support to early career research scientists and established investigators in other fields to develop independent research skills in antiviral drug research and development by implementing Developmental Research Projects and Mentored Project Programs. The Core Director has significant expertise in the coordination of program projects and large-scale multi-institutional consortia. He served as Director of the HINT consortium, a program project consisting of over 13 PIs at 10 institutions focusing on systems-based analysis of immune responses to HIV (P01 AI090935), and as Deputy Director of additional multi-institutional consortia; Fluomics (U19 AI106754) and Fluomics: The Next Generation (U19 AI135972), which focus on the use of systems-level technologies to identify host determinants of viral pathogenesis, both for influenza and SARS-CoV-2. More recently, he was named the PD/PI on a multi-PD/PI NIAID Vaccine Adjuvant Discovery Program contract (75N93019C00046), the PD/PI on the multi-PD/PI NIAID Reversing Immune Dysfunction for HIV-1 Eradication Program (UM1 AI164561), and the PD of the DoD program Development and Advancement of Broad-Spectrum Respiratory Antivirals (DABRA) (W81XWH-20-1-0270). Core Deputy Director Dr. García-Sastre has been the PD of the two Fluomics programs as well as the DABRA program mentioned above and is thus very well suited to assist Dr. Chanda in successfully leading this multi- disciplinary program. Deputy Director García-Sastre will oversee the Mentored Project to be initiated in year 2, supported by his experience in organizing the highly successful Fluomics program for junior level investigators (EMBED). Deputy Director Dr. Arnab Chatterjee will take responsibility for oversight of the Developmental Research program and has substantial experience relevant to the development and advancement of specific antivirals and related basic science studies, having advanced multiple drug candidates to major technology development licensing deals with Bristol-Myers Squibb, AbbVie, and Gilead as well as clinical trials.
摘要 行政核心将通过以下方式协调CAMPP AViDD中心:1)建立组织 以执行委员会为中心的结构,执行委员会负责-与主任、副主任、 和科学咨询委员会(SAB)-监测总体计划进展并就以下问题做出决定 人员配备计划、资源分配、核心使用和其他政策;2)协调定期举行 中心研究团队之间的电话会议,并组织年度会议 PIS、选定的关键人员、SAB和NIAID,以及NIAID的年度反向现场访问;3) 协助该联合体的调查人员进行试剂和数据共享、手稿准备、IND 筹备工作,及时向公众传播数据,并向 NIAID;以及4)为早期职业研究科学家和知名研究人员提供支持 在抗病毒药物研发方面培养独立研究技能的其他领域 实施发展研究项目和指导项目计划。核心董事 在协调计划项目和大型多机构项目方面拥有丰富的专业知识 财团。他曾担任HINT联盟的董事,该联盟是一个由13名PI组成的计划项目 在专注于艾滋病毒免疫反应系统分析的10个机构(P01 AI090935), 并担任其他多机构财团的副主任;福陆经济学(U19 AI106754)和 通量组学:下一代(U19 AI135972),专注于系统级技术的使用 识别病毒致病的宿主决定因素,包括流感和SARS-CoV-2。最近, 他被任命为多PD/PI NIAID疫苗佐剂发现计划合同的PD/PI (75N93019C00046),Pd/PI对多重Pd/PI逆转HIV-1免疫功能障碍的影响 根除计划(UM1 AI164561)和国防部PD计划的发展和推进 广谱呼吸抗病毒药物(Dabra)(W81XWH-20-1-0270)。核心副主任Dr。 García-Sastre一直是这两个通量组学计划以及Dabra计划的PD 如上所述,因此非常适合协助昌达博士成功地领导这项多领域的 纪律处分程序。副主任García-Sastre将监督将于#年启动的指导项目 二年级,得到了他为青少年组织非常成功的福陆经济学计划的经验的支持 级别调查员(嵌入)。副主任Arnab Chatterjee博士将负责监督 发展研究计划,并有丰富的开发经验 以及特定的抗病毒药物和相关基础科学研究的进展,具有先进的多重 与百时美施贵宝,艾伯维, 和吉利德以及临床试验。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SUMIT K CHANDA其他文献

SUMIT K CHANDA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SUMIT K CHANDA', 18)}}的其他基金

Determinants of HIV-1 innate immune sensing and its role in shaping the lymphoid environment.
HIV-1 先天免疫感应的决定因素及其在塑造淋巴环境中的作用。
  • 批准号:
    10712594
  • 财政年份:
    2023
  • 资助金额:
    $ 678.15万
  • 项目类别:
Center for Antiviral Medicines & Pandemic Preparedness (CAMPP)
抗病毒药物中心
  • 批准号:
    10514317
  • 财政年份:
    2022
  • 资助金额:
    $ 678.15万
  • 项目类别:
Reversing Immune Dysfunction for HIV-1 Eradication
逆转免疫功能障碍以根除 HIV-1
  • 批准号:
    10469447
  • 财政年份:
    2021
  • 资助金额:
    $ 678.15万
  • 项目类别:
Reversing Immune Dysfunction for HIV-1 Eradication
逆转免疫功能障碍以根除 HIV-1
  • 批准号:
    10313784
  • 财政年份:
    2021
  • 资助金额:
    $ 678.15万
  • 项目类别:
Reversing Immune Dysfunction for HIV-1 Eradication
逆转免疫功能障碍以根除 HIV-1
  • 批准号:
    10540209
  • 财政年份:
    2021
  • 资助金额:
    $ 678.15万
  • 项目类别:
Project 2 - Host-virus networks regulating flu replication and host responses ex vivo
项目 2 - 调节流感复制和宿主离体反应的宿主病毒网络
  • 批准号:
    10080715
  • 财政年份:
    2018
  • 资助金额:
    $ 678.15万
  • 项目类别:
Early development of small molecule dendritic cell immunopotentiators for the treatment of solid tumors
用于治疗实体瘤的小分子树突状细胞免疫增强剂的早期开发
  • 批准号:
    10180915
  • 财政年份:
    2018
  • 资助金额:
    $ 678.15万
  • 项目类别:
A Novel Conformation of the ZIKV Protease Provides a Unique 3D Scaffold for Discovering Allosteric Protease Inhibitors as Direct Anti-virals, via HT and Virtual Screening, and Protein Engineering
ZIKV 蛋白酶的新颖构象为通过 HT 和虚拟筛选以及蛋白质工程发现变构蛋白酶抑制剂作为直接抗病毒药物提供了独特的 3D 支架
  • 批准号:
    9757689
  • 财政年份:
    2018
  • 资助金额:
    $ 678.15万
  • 项目类别:
Project 2 - Host-virus networks regulating flu replication and host responses ex vivo
项目 2 - 调节流感复制和宿主离体反应的宿主病毒网络
  • 批准号:
    10322693
  • 财政年份:
    2018
  • 资助金额:
    $ 678.15万
  • 项目类别:
Project 2 - Host-virus networks regulating flu replication and host responses ex vivo
项目 2 - 调节流感复制和宿主离体反应的宿主病毒网络
  • 批准号:
    10322687
  • 财政年份:
    2018
  • 资助金额:
    $ 678.15万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 678.15万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 678.15万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 678.15万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 678.15万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 678.15万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 678.15万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 678.15万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 678.15万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 678.15万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 678.15万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了